News and Announcements
Actinogen Medical Annual Report to Shareholders 2016
- Published October 25, 2016 6:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
24th October 2016, ASX Announcement
Chaimans Address
It is a great pleasure on behalf of the Board to present the 2016 Actinogen Medical Annual Report. This year’s many achievements are the result of careful and prudent long-term strategic planning and our strong commitment to bring our distinctive novel drug Xanamem™ to market with a commercial focus on treating Alzheimer’s disease.
Xanamem™ represents a new approach to treating Alzheimer’s disease – a condition with a significant unmet medical need that threatens to place a huge burden on society. Xanamem works by blocking the development and regeneration of cortisol – the “stress hormone” – which appears to contribute to the cognitive impairment, amyloid plaques and neural death, that are the hallmarks of Alzheimer’s disease.
Alzheimer’s disease is one of the nation’s largest public health crises and has a debilitating effect on patients and their loved ones. Currently, Alzheimer’s is the second-leading cause of death in Australia according to the ABS, and sixth-leading cause of death in the United States.
To view the full announcement, please click on the button below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
